 Kathleen Bickel
Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palliative Care | 6 | 2022 | 643 | 1.100 |
Why?
| | Terminal Care | 4 | 2019 | 210 | 0.880 |
Why?
| | Neoplasms | 7 | 2023 | 2112 | 0.770 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 545 | 0.470 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2019 | 751 | 0.400 |
Why?
| | Quality of Life | 3 | 2023 | 2392 | 0.380 |
Why?
| | Bodily Secretions | 1 | 2008 | 2 | 0.320 |
Why?
| | Veterans | 1 | 2019 | 1232 | 0.320 |
Why?
| | Mouth | 1 | 2008 | 68 | 0.310 |
Why?
| | Death | 1 | 2008 | 107 | 0.300 |
Why?
| | Respiratory Sounds | 1 | 2008 | 114 | 0.300 |
Why?
| | Oncologists | 2 | 2016 | 31 | 0.270 |
Why?
| | Advance Care Planning | 2 | 2020 | 197 | 0.260 |
Why?
| | Advance Directives | 2 | 2023 | 69 | 0.230 |
Why?
| | Medical Oncology | 2 | 2023 | 230 | 0.200 |
Why?
| | Living Wills | 1 | 2020 | 8 | 0.190 |
Why?
| | Decision Making | 2 | 2017 | 792 | 0.180 |
Why?
| | Hospice Care | 1 | 2023 | 187 | 0.170 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2020 | 69 | 0.170 |
Why?
| | Emergency Medicine | 1 | 2022 | 239 | 0.160 |
Why?
| | Suicide, Assisted | 1 | 2017 | 19 | 0.140 |
Why?
| | Informed Consent | 1 | 2017 | 163 | 0.140 |
Why?
| | United States Department of Veterans Affairs | 1 | 2019 | 556 | 0.130 |
Why?
| | Low Back Pain | 1 | 2017 | 95 | 0.130 |
Why?
| | Psychology | 1 | 2016 | 83 | 0.130 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 551 | 0.130 |
Why?
| | Culture | 1 | 2016 | 126 | 0.130 |
Why?
| | Physician-Patient Relations | 2 | 2016 | 466 | 0.130 |
Why?
| | Pandemics | 2 | 2020 | 1333 | 0.130 |
Why?
| | Humans | 16 | 2023 | 115901 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 343 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 335 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 254 | 0.120 |
Why?
| | Home Care Services | 1 | 2017 | 226 | 0.120 |
Why?
| | Physicians | 1 | 2022 | 774 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 682 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 275 | 0.110 |
Why?
| | Quality Improvement | 1 | 2020 | 956 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 686 | 0.110 |
Why?
| | Societies, Medical | 1 | 2016 | 690 | 0.100 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 990 | 0.100 |
Why?
| | Hospitalization | 1 | 2020 | 1761 | 0.100 |
Why?
| | Quality of Health Care | 1 | 2016 | 578 | 0.100 |
Why?
| | United States | 4 | 2020 | 12338 | 0.090 |
Why?
| | Clinical Competence | 1 | 2017 | 918 | 0.090 |
Why?
| | Caregivers | 1 | 2016 | 714 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1403 | 0.080 |
Why?
| | Muscarinic Antagonists | 1 | 2008 | 27 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1177 | 0.080 |
Why?
| | Aged | 4 | 2019 | 19299 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2017 | 1870 | 0.060 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2003 | 16 | 0.060 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2003 | 23 | 0.050 |
Why?
| | Camptothecin | 1 | 2003 | 97 | 0.050 |
Why?
| | Forecasting | 1 | 2022 | 332 | 0.050 |
Why?
| | Social Work | 1 | 2020 | 75 | 0.040 |
Why?
| | Patient Care Planning | 1 | 2020 | 142 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 533 | 0.040 |
Why?
| | Goals | 1 | 2020 | 159 | 0.040 |
Why?
| | Research Personnel | 1 | 2020 | 154 | 0.040 |
Why?
| | Medical Assistance | 1 | 2017 | 14 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 240 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 253 | 0.040 |
Why?
| | Publication Bias | 1 | 2017 | 38 | 0.040 |
Why?
| | Canada | 1 | 2017 | 337 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 182 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1359 | 0.030 |
Why?
| | Patient Preference | 1 | 2016 | 171 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 970 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2020 | 801 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2016 | 595 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1177 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2017 | 647 | 0.030 |
Why?
| | Female | 5 | 2020 | 60081 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1216 | 0.020 |
Why?
| | Qualitative Research | 1 | 2016 | 964 | 0.020 |
Why?
| | Male | 4 | 2020 | 56127 | 0.020 |
Why?
| | Middle Aged | 3 | 2016 | 27083 | 0.020 |
Why?
| | Adult | 3 | 2016 | 30817 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2003 | 17 | 0.010 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2003 | 45 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 9165 | 0.010 |
Why?
| | Etoposide | 1 | 2003 | 149 | 0.010 |
Why?
| | Maximum Tolerated Dose | 1 | 2003 | 182 | 0.010 |
Why?
| | Area Under Curve | 1 | 2003 | 277 | 0.010 |
Why?
| | Cisplatin | 1 | 2003 | 263 | 0.010 |
Why?
| | Antigens, Neoplasm | 1 | 2003 | 224 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1319 | 0.010 |
Why?
| | Cohort Studies | 1 | 2003 | 4961 | 0.010 |
Why?
|
|
Bickel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|